TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
复制标题
TNF α 抑制作为某些风湿病和胃肠道疾病的治疗方式。
DOI：
10.2174/187153009789044347
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
M. Pierer
中科院分区：
文献类型：
--
作者：
M. Wiedmann;J. Mössner;C. Baerwald;M. Pierer
随着特异性靶向肿瘤坏死因子（TNF）α的生物制剂的发展，我们对炎症性疾病的治疗方法发生了巨大变化。目前有三种抗TNF α药物可用：依那西普，英夫利昔单抗和阿达木单抗。依那西普是一种重组融合蛋白，可单独使用或与其他药物联合使用，用于治疗类风湿性关节炎、幼年型类风湿性关节炎、银屑病关节炎、银屑病和强直性脊柱炎等疾病。英夫利昔单抗（一种嵌合人源化单克隆抗体）和阿达木单抗（一种全人单克隆抗体）已被批准用于治疗类风湿性关节炎、银屑病、银屑病关节炎、强直性脊柱炎和中度至重度克罗恩病。英夫利西单抗也被批准用于溃疡性结肠炎。另一种抗TNF α药物赛妥珠单抗（certolizumab pegol）由于缺乏足够的疗效而被拒绝批准作为活动性克罗恩病的治疗选择。治疗类风湿性关节炎患者的III期研究仍在进行中。这篇综述文章的目的是总结各种治疗适应症，基础研究，安全性和妊娠期间的使用，以及抗TNF治疗的未来方向。
With the development of biologicals that specifically target tumor necrosis factor (TNF)alpha, our therapeutic approach to inflammatory diseases has dramatically changed. There are currently three anti-TNFalpha drugs available: etanercept, infliximab, and adalimumab. Etanercept is a recombinant fusion protein that can be used alone or in combination with other medications for conditions such as rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis. Infliximab, a chimeric humanized monoclonal antibody and adalimumab, a fully human monoclonal antibody are approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and moderate to severe Crohn's disease. Infliximab is also approved for ulcerative colitis. Another anti-TNFalpha drug, certolizumab pegol, was declined approval as treatment option for active Crohn's disease due to a lack of sufficient efficacy. Phase III studies for the treatment of rheumatoid arthritis patients are still pending. It is the goal of this review article to summarize various therapeutic indications, underlying studies, safety, and use during pregnancy, as well as future directions for anti-TNF therapies.